Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab beta for primary membranous nephropathy
ChiCTR2600134998Phase 4Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of obinutuzumab in idiopathic membranous glomerulonephritis (IMG), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Overall response rate at week 52. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2600134998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134998.